| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a799d17d5f808bee28dc9a15345a54f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 |
| filingDate |
2016-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23cf8cbf977c05beb154a262e900b29f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c53a22ecc9091c8db984a30e3bc9926
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9334d6d396c199f51b2a83b5b0ae25b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b3eb3561524efa2868aa46dba62783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b332e1572f95a464ec66b586471d3529
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_591b4ff806c6ac50610adbeabf12ce05 |
| publicationDate |
2017-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017199070-A1 |
| titleOfInvention |
Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
| abstract |
The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N- Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021111330-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018297653-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021111320-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018297653-C1 |
| priorityDate |
2016-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |